Browse drugs

…ncer that have a poor prognosis with limited treatment options. Tarlatamab is a first-in-class, half-life extended delta-like ligand 3 (DL…

…ved). The best overall response was SD (RECIST 1.1).Conclusions VAX014 monotherapy is well tolerated with evidence of activity in both…

…ommon Grade 1/2 events occurred in ≤20% of patients.Conclusions Imneskibart + low-dose SC aldesleukin possess a unique mechanism of action …

…, et al. KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectabl…

…able engagement by tumor cell-opsonizing antibodies. Therefore, F9H4 represents a new opportunity in cancer immunotherapy research.E…

…uated NK cell survival, expansion, and cytotoxic activity after rhChemerin treatment.Results We observed that rhChemerin increased calcium…

…suggesting that DC inclusion dampens the macrophage response to bemcentinib.9 Separation of macrophages by A375 state was further reflected…

…fy proteins that synergize with IL-12 locally and systemically. IL-12 IVEP was also combined with intratumoral delivery of cowpea mos…

…ophils in both tumor sites, with stronger effects observed with MQ833.Conclusions Intravesical delivery of rMVA vectors MQ710 and MQ8…

…several T2DM drugs (metformin, rosiglitazone, canagliflozin and sitagliptin) on mouse and human ovarian cancer cells in vitro, and the effe…

…57BL/6) mice and treated 7d later with equivalent virus dose of C027 (C134+IL27) or parent virus (C134) or vehicle control. To asses…

… studies that demonstrated an enhanced anti-tumor response with Vidutolimod treatment, especially in combination with anti-PD-1 therapy.Eth…